Which Weight Management Treatment Suits Your Needs?
Ozempic v Wegovy: Understanding the Critical Legal Distinction
When comparing Ozempic v Wegovy, the fundamental difference isn't clinical—it's legal and licensing-based. Both contain identical semaglutide, but Ozempic holds an MHRA licence exclusively for type 2 diabetes management. Wegovy received separate MHRA approval specifically for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. Promoting Wegovy for weight management constitutes illegal off-label advertising in the UK, making this distinction crucial for patient safety and regulatory compliance.
This is where the Wegovy vs Mounjaro comparison becomes more relevant for weight management seekers. Mounjaro (tirzepatide) represents a newer dual-agonist approach, targeting both GIP and GLP-1 receptors simultaneously, whilst Wegovy focuses solely on GLP-1 pathways. Both hold proper MHRA licensing for weight management, ensuring you're accessing appropriately regulated treatments through our GPhC-registered pharmacy (#9012878).
Wegovy vs Mounjaro Pricing: Transparent Cost Comparison
Understanding the financial commitment helps inform your Ozempic v Wegovy vs Mounjaro decision. Wegovy pricing begins at £79.99 for the 0.25mg starter dose (weeks 1-4) with code FIRST40, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenience without complex calculations—the Intro Trio (0.25mg, 0.5mg, 1mg) offers your first three months for £299.99, whilst the Progress Duo (0.5mg & 1mg) costs £189.99.
Returning customers benefit from code DOSE25 at checkout, maintaining competitive pricing throughout your treatment journey. Both Wegovy and Mounjaro require similar prescriber oversight and clinical assessment processes, with EverydayMeds providing 24-hour express review options for faster treatment initiation. The convenience of accessing both treatments through one trusted pharmacy eliminates the complexity of comparing multiple suppliers whilst ensuring consistent cold-chain delivery standards.
Clinical Evidence: STEP Trials and Treatment Efficacy
The clinical foundation supporting your Ozempic v Wegovy choice centres on robust STEP trial data published by Wilding et al. in the New England Journal of Medicine, 2021. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1, compared to 2.4% with placebo. The STEP 5 study demonstrated sustained clinically studied weight loss at two years, whilst SELECT trial data revealed a 20% reduction in major cardiovascular events.
Mounjaro's clinical profile stems from different trial designs and patient populations, making direct percentage comparisons inappropriate and potentially misleading. Both treatments demonstrated efficacy when used as prescription-only medicines alongside lifestyle interventions, but individual responses vary significantly based on adherence, genetic factors, and concurrent health conditions.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones that regulate appetite and satiety. Once injected weekly via the FlexTouch pen device, semaglutide binds to GLP-1 receptors in your brain's appetite centres, promoting feelings of fullness after smaller meals. This mechanism may reduce food cravings and slow gastric emptying, helping you feel satisfied with reduced caloric intake. Unlike quick fixes or appetite suppressants, Wegovy works with your body's existing regulatory systems to support sustainable weight management. The treatment requires commitment to dose escalation from 0.25mg through to 2.4mg maintenance, ensuring optimal therapeutic response whilst minimising potential side effects.
Streamlined Ordering Process: Assessment to Delivery
Accessing Wegovy through EverydayMeds eliminates the complexity often associated with specialist weight management services. Our 3-minute online clinical assessment captures essential medical history, current medications, and eligibility criteria required for safe prescribing. Qualified prescribers review your assessment within 72 hours (or 24 hours with express service), ensuring thorough evaluation against MHRA licensing criteria. Once approved, your Wegovy ships via next-day delivery using temperature-controlled packaging that maintains the required 2-8°C cold-chain throughout transit. This seamless process removes barriers to accessing legitimate, licensed treatment whilst maintaining clinical safety standards throughout.
Storage and Practical Considerations
Wegovy offers practical advantages in daily management, particularly regarding storage flexibility compared to Mounjaro alternatives. Each FlexTouch pen remains stable in refrigerated conditions (2-8°C) until first use, then maintains potency for up to 6 weeks at room temperature below 30°C—double Mounjaro's 21-day room temperature stability. This extended stability proves valuable for travel, work schedules, or situations where refrigeration access becomes limited. The weekly injection schedule fits easily into routine healthcare management, whilst the dose escalation protocol (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg) provides structured progression toward optimal therapeutic response over approximately 16-17 weeks.
Dual-Supply Advantage: Why Choose EverydayMeds for Both Options
Unlike specialist clinics focusing on single treatments, EverydayMeds supplies both Wegovy and Mounjaro through one integrated service. This unique position allows our prescribers to recommend the most appropriate treatment based on your individual clinical profile, rather than limiting choices to available inventory. Your medical history, current medications, lifestyle factors, and treatment goals all influence whether GLP-1 single agonist (Wegovy) or GIP + GLP-1 dual agonist (Mounjaro) approaches better suit your needs.
Both treatments require identical assessment processes, ongoing monitoring, and lifestyle commitment to reduced-calorie diet and increased physical activity. Having access to both options through one trusted GPhC-registered pharmacy ensures continuity of care, consistent clinical oversight, and simplified logistics for prescription renewals, dose adjustments, or treatment switches if clinically indicated by your prescriber.
Complete Your Assessment: Next Steps to Treatment
Understanding the Ozempic v Wegovy distinction alongside Wegovy vs Mounjaro comparisons empowers informed treatment decisions based on licensed, appropriate options. Both Wegovy and Mounjaro remain available through our streamlined assessment process, with transparent pricing, professional clinical oversight, and next-day delivery maintaining treatment continuity. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 for continued access to competitive pricing structures. Your treatment journey begins with our comprehensive clinical assessment, designed to ensure safe, appropriate prescribing aligned with MHRA licensing requirements. Visit our weight management collection to start your assessment today and access expert guidance on selecting between these evidence-based treatment options.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
